肉毒素对肌痉挛的单组剂量安全性试验NJEM.pdfVIP

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity The TOWER study Jörg Wissel, MD, FRCP * ABSTRACT Djamel Bensmail, MD, Objective: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) PhD* of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. Joaquim J. Ferreira, MD, Methods: In this prospectiv